Tardive Dyskinesia: Barriers to the Professional Recognition of an Iatrogenic Disease
نویسندگان
چکیده
منابع مشابه
Tardive dyskinesia: barriers to the professional recognition of an iatrogenic disease.
Tardive dyskinesia (TD), once regarded by psychiatrists as a rare occurrence, is currently recognized as the most pervasive side effect (other than sedation) ofantipsychotic medication. Early reports linking antipsychotic drugs to TD met with considerable criticism. Mounting evidence concerning high prevalence of the disorder among psychiatric patients has led to a general acceptance of the syn...
متن کاملAn investigation on the relationship between risk factors and severity of tardive dyskinesia
The focus of most previous research concerning tardive dyskinesia has been on the impact of risk factors on the development( incidence) of this syndrome. In this paper, we report our results on the relationship between risk factors and the severity of tardive dyskinesia. A total of 33 patients diagnosed as tardive dyskinesia with no other medical illness studied: 21 males and 12 females with a ...
متن کاملTardive dyskinesia due to risperidone.
Tardive dyskinesia (TD) is a neuroleptic-induced movement disorder, and is recognised as a late adverse effect of neuroleptic drugs. We report a case of TD associated with risperidone, a new “atypical” antipsychotic drug. Risperidone has a high affinity for D2 dopamine and 5-HT2 receptors [8 1. Thus, it produces less extrapyramidal side effects (EPS) than classical neuroleptics. Also, risperido...
متن کاملFactors related to tardive dyskinesia.
The authors found a 31% incidence of tardive dyskinesia among 261 schizophrenic outpatients treated with neuroleptics. Multiple linear logistic regression analysis revealed a higher incidence of tardive dyskinesia among elderly patients, those with longer records of hospitalization, those for whom neuroleptic medication had little therapeutic effect, and those treated with fluphenazine. Patient...
متن کاملMetoclopramide and tardive dyskinesia.
Metoclopramide (MCP) is a D-2 receptor blocker (Kebabian and Calne 1979), which has been available by prescription in the United States since 1979 for use as an antiemetic in a wide range of situations. One of the common indications for MCP is the &eatment of diabetic gastroparesis (Physicians' Desk Reference 1993). A few recent reports suggest that diabetes mellitus may be a risk factor for ta...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Health and Social Behavior
سال: 1986
ISSN: 0022-1465
DOI: 10.2307/2136311